311 related articles for article (PubMed ID: 22749834)
1. Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: Impact of formulation on physicochemical and immunological characteristics.
Tafaghodi M; Saluja V; Kersten GF; Kraan H; Slütter B; Amorij JP; Jiskoot W
Vaccine; 2012 Aug; 30(36):5341-8. PubMed ID: 22749834
[TBL] [Abstract][Full Text] [Related]
2. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W
Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455
[TBL] [Abstract][Full Text] [Related]
3. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
Pawar D; Mangal S; Goswami R; Jaganathan KS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
[TBL] [Abstract][Full Text] [Related]
4. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W
Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248
[TBL] [Abstract][Full Text] [Related]
5. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?
Slütter B; Bal SM; Que I; Kaijzel E; Löwik C; Bouwstra J; Jiskoot W
Mol Pharm; 2010 Dec; 7(6):2207-15. PubMed ID: 21043518
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally.
Mangal S; Pawar D; Garg NK; Jain AK; Vyas SP; Rao DS; Jaganathan KS
Vaccine; 2011 Jul; 29(31):4953-62. PubMed ID: 21575664
[TBL] [Abstract][Full Text] [Related]
7. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
8. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
Borges O; Cordeiro-da-Silva A; Tavares J; Santarém N; de Sousa A; Borchard G; Junginger HE
Eur J Pharm Biopharm; 2008 Jun; 69(2):405-16. PubMed ID: 18364251
[TBL] [Abstract][Full Text] [Related]
9. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
Jaganathan KS; Vyas SP
Vaccine; 2006 May; 24(19):4201-11. PubMed ID: 16446012
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
11. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen.
Slütter B; Soema PC; Ding Z; Verheul R; Hennink W; Jiskoot W
J Control Release; 2010 Apr; 143(2):207-14. PubMed ID: 20074597
[TBL] [Abstract][Full Text] [Related]
12. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
Hagenaars N; Verheul RJ; Mooren I; de Jong PH; Mastrobattista E; Glansbeek HL; Heldens JG; van den Bosch H; Hennink WE; Jiskoot W
J Control Release; 2009 Dec; 140(2):126-33. PubMed ID: 19712713
[TBL] [Abstract][Full Text] [Related]
13. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice.
Bal SM; Slütter B; Verheul R; Bouwstra JA; Jiskoot W
Eur J Pharm Sci; 2012 Mar; 45(4):475-81. PubMed ID: 22009113
[TBL] [Abstract][Full Text] [Related]
14. Preparation, characterization and
Mosafer J; Sabbaghi AH; Badiee A; Dehghan S; Tafaghodi M
Asian J Pharm Sci; 2019 Mar; 14(2):216-221. PubMed ID: 32104453
[TBL] [Abstract][Full Text] [Related]
15. Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response.
Pawar D; Jaganathan KS
Drug Deliv; 2016; 23(1):185-94. PubMed ID: 24825494
[TBL] [Abstract][Full Text] [Related]
16. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B.
Khatri K; Goyal AK; Gupta PN; Mishra N; Vyas SP
Int J Pharm; 2008 Apr; 354(1-2):235-41. PubMed ID: 18182259
[TBL] [Abstract][Full Text] [Related]
17. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations.
Bal SM; Slütter B; van Riet E; Kruithof AC; Ding Z; Kersten GF; Jiskoot W; Bouwstra JA
J Control Release; 2010 Mar; 142(3):374-83. PubMed ID: 19932723
[TBL] [Abstract][Full Text] [Related]
18. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
Borges O; Silva M; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
Int Immunopharmacol; 2008 Dec; 8(13-14):1773-80. PubMed ID: 18801462
[TBL] [Abstract][Full Text] [Related]
19. Preparation and evaluation of antigen/N-trimethylaminoethylmethacrylate chitosan conjugates for nasal immunization.
Liu Q; Zhang C; Zheng X; Shao X; Zhang X; Zhang Q; Jiang X
Vaccine; 2014 May; 32(22):2582-90. PubMed ID: 24681230
[TBL] [Abstract][Full Text] [Related]
20. Lipopolysaccharide derived alginate coated Hepatitis B antigen loaded chitosan nanoparticles for oral mucosal immunization.
Saraf S; Jain S; Sahoo RN; Mallick S
Int J Biol Macromol; 2020 Jul; 154():466-476. PubMed ID: 32194106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
